Search company, investor...

Myelo Therapeutics

myelotherapeutics.com

Founded Year

2013

Stage

Acquired | Acquired

Total Raised

$6M

About Myelo Therapeutics

Myelo Therapeutics develops medical countermeasure drugs for the treatment of acute radiation syndrome. It offers a small molecule-based oral therapy that assists in reducing the risk of chemotherapy-induced myelosuppression (CIM) and radiation in patients across various cancer types and radio-chemotherapy regimens. The company was founded in 2013 and is based in Berlin, Germany. In December 2022, Myelo Therapeutics was acquired by Eckert & Ziegler. The terms of the transaction were not disclosed.

Headquarters Location

Kastanienallee 56

Berlin, D-10119,

Germany

+49 (0)170 9126 402

Missing: Myelo Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Myelo Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Myelo Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Myelo Therapeutics is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Myelo Therapeutics Patents

Myelo Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Cytokines
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/25/2019

Clusters of differentiation, Monoclonal antibodies, Radiation health effects, Cytokines, Immunology

Application

Application Date

9/25/2019

Grant Date

Title

Related Topics

Clusters of differentiation, Monoclonal antibodies, Radiation health effects, Cytokines, Immunology

Status

Application

Latest Myelo Therapeutics News

DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

Aug 4, 2022

A DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Schlagwort(e): Vertrag Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures 04.08.2022 / 10:07 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. BERLIN, GERMANY, August 04, 2022 Myelo Therapeutics GmbH, an Affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) and member of a pan-European consortium of research and industry partners, was selected to receive grants worth approximately 17 million Euro for the development of its medical countermeasure (MCM) against acute radiation syndrome. The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period. Anzeige Basiswert Myelo Therapeutics international team, which started 2019 its countermeasure program with the support of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is uniquely positioned to establish a comprehensive research network and develop novel countermeasures for deployment in EU and NATO territory. Beyond its potential as a medical countermeasure, the MCM portfolio has several promising clinical applications in mitigating radiation and chemotherapy-induced toxicity in nuclear medicine and (radiation) oncology. The funds are part of a 49 million EUR grant that the European Defense Fund intends to allocate to the consortium led by the French Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), a group that is working on military medical countermeasures (MCMs) against Chemical Biological Radiological and Nuclear (CRBN) threats. The project "European agile network for medical COUNTERmeasures Against CBRN Threats" (COUNTERACT) aims to establish a robust and agile network within the EU to be capable of developing and deploying medical countermeasures (MCMs) against major Chemical, Biological, Radiological, and Nuclear (CRBN) threats such as terror plots, nuclear accidents, weapon development and epidemics caused by emerging or re-emerging high consequence pathogens. COUNTERACT will increase EU preparedness for immediate response to such threats. About Myelo Therapeutics: Myelo Therapeutics GmbH is a pharmaceutical company based in Berlin, Germany, developing innovative medical countermeasure treatments against Chemical, Biological, Radiological, and Nuclear (CRBN) threats and Supportive Care therapies in Oncology and Nuclear Medicine. For more information, visit www.myelotherapeutics.com . About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy. The company offers a broad range of services and products along the radioactive value chain, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse. About Acute Radiation Syndrome: ARS, also known as radiation toxicity or radiation sickness, is an acute illness that presents after exposure of large portions of the body to high levels of radiation, like those that might be experienced during a radiological/nuclear incident or attack. The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting one of the major causes of mortality. Contact:

Myelo Therapeutics Frequently Asked Questions (FAQ)

  • When was Myelo Therapeutics founded?

    Myelo Therapeutics was founded in 2013.

  • Where is Myelo Therapeutics's headquarters?

    Myelo Therapeutics's headquarters is located at Kastanienallee 56, Berlin.

  • What is Myelo Therapeutics's latest funding round?

    Myelo Therapeutics's latest funding round is Acquired.

  • How much did Myelo Therapeutics raise?

    Myelo Therapeutics raised a total of $6M.

  • Who are the investors of Myelo Therapeutics?

    Investors of Myelo Therapeutics include Eckert & Ziegler, Eckert Life Science Accelerator, National Institutes of Health, IBB Beteiligungsgesellschaft, JSC Valenta Pharmaceuticals and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.